In 2020, Sheila Gujrathi, M.D. earned $4.17M in total compensation at Gossamer Bio, Inc., including $494.00K salary, $276.68K bonus and $2.76M in stock. Most recently acquired 2,500 shares in Jun 2024. Currently holds stock worth $16.07M. Led Gossamer Bio, Inc. as CEO for 2 years.
Compensation History
Annual executive compensation data for Sheila Gujrathi, M.D., including salary, bonuses, and stock awards.
Year
2020
Total Compensation
$4.17M
Salary
$494.00K
Bonus
$276.68K
Other
$642.03K
Salary
$494.00KBoard Justification
The compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on our annual and long-term business objectives necessary to create stockholder value.
Bonus
$276.68KBoard Justification
Prorated incentive bonus for 2020 paid upon the time of her transition in 2020.
Other Compensation
$642.03KBoard Justification
Includes $66,000 in accrued but unused payout of paid time off, continued payment of her base salary for 12 months per her transition agreement, and healthcare coverage at our expense in the amount of $4,033 in connection with her transition.
Restricted Stock
Board Justification
Restricted stock units that vested upon her transition agreement, which included 18 months’ accelerated vesting of her outstanding restricted stock.
Performance Metrics
Corporate performance goals were set prior to the onset of the COVID pandemic and were not adjusted, with a corporate performance percentage of 105% achieved.
Sheila Gujrathi, M.D.
Ex-CEO of Gossamer Bio, Inc.
Education
M.D. from the University of Texas, Southwestern
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
CEO of Gossamer Bio, Inc. for
2 years 10 months (Jan 2018 - Nov 2020)
Previous Experience
Chief Operating Officer at Gossamer Bio, Inc.
Other Gossamer Bio, Inc. CEOs
Holdings
Track Sheila Gujrathi, M.D.'s stock holdings and portfolio value over time.
Insider Trading
Sheila Gujrathi, M.D.'s recent stock transactions, purchases, and sales filed with the SEC.
2,500 shares
JANX
Jun 26, 2024
Received
189,500 shares
GOSS
Feb 14, 2020
Received
$167.98K
GOSS at $16.80/share
Sep 27, 2019
Purchase
Rivals
Compare Sheila Gujrathi, M.D. with competitor CEOs and industry peers.